A paper detailing the findings has been published as an early online version and is scheduled for publication in the September 6 issue of the Journal of Alzheimer's Disease.
According to lead investigator Vivian Y. H. Hook, PhD, professor of the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences and professor of neurosciences, pharmacology and medicine at the UCSD School of Medicine, this is major news for scientists studying Alzheimer's disease.
"The finding is especially exciting because E64d has previously been shown safe for use in humans, so we believe the compound has strong potential as a new therapy for Alzheimer's disease," said Hook.
Increased Aâ levels in the brain are associated with the development of memory loss and amyloid plaque, the hallmark of Alzheimer's disease. Aâ peptides are "cut" out from a larger protein called the amyloid precursor protein (APP) by an enzymatic "scissor" called â-secretase, and aggregate to form plaques in the brain regions responsible for memory.
E64d reduces Aâ by inhibiting the â-secretase "scissors" from "cutting" the APP chain into smaller toxic Aâ peptides. But in this study, the researchers found that the compound actually increases the activity of a protease called BACE1 which, to date, has been regarded as the primary â-secretase. Instead, E64d appears to lower brain Aâ by inhibiting the â-secretase activity of another protease, Cathepsin B.
"The study indicates Cathepsin B as a new target for therapeutic inhibition of Aâ production and subsequent improved memory function," said Hook. "This is an important finding because we show that â-secretase inhibition can occur with Cathepsin B inhibition and without BACE1 inhibition."
The researchers studied both old and young transgenic Alzheimer's disease mice, and found that memory loss improved in both. In young mice, feeding E64d prevented development of memory loss; in old mice with memory loss, it improved memory.
The study builds upon work published in March 2008 that first demonstrated that inhibitors of Cathepsin B resulted in improved memory and reduction of Aâ and amyloid plaque; but in that study, the drug was administered directly into the brains of AD mice. In the new study, oral administration of the drug was efficacious and could lead the way to clinical trials in humans.
Co-authors of the study were Gregory Hook, PhD, of American Life Science Pharmaceuticals in San Diego, and Mark Kindy of the Medical University of South Carolina, as well as the Ralph H. Johnson VA Medical Center, and Applied Neurotechnology, Inc., in Charleston, SD.
G. Hook is an employee and has equity in American Life Science Pharmaceuticals (ALSP); V. Hook is chair of ALSP's scientific advisory board and holds equity in the company, and Kindy holds equity in Applied Neurotechnology, relationships disclosed to their institutions.
The study was supported in part by the National Institute on Aging of the National Institutes of Health and the Alzheimer's Drug Development Foundation.
Debra Kain | EurekAlert!
Tag it EASI – a new method for accurate protein analysis
19.06.2018 | Max-Planck-Institut für Biochemie
How to track and trace a protein: Nanosensors monitor intracellular deliveries
19.06.2018 | Universität Basel
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
Light detection and control lies at the heart of many modern device applications, such as smartphone cameras. Using graphene as a light-sensitive material for...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
19.06.2018 | Physics and Astronomy
19.06.2018 | Life Sciences
19.06.2018 | Physics and Astronomy